Next-Generation Biomanufacturing Market is predicted to reach USD 54.0 billion at a CAGR of 9.90% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Next-Generation Biomanufacturing Market”.

The Next-Generation Biomanufacturing market is estimated to register a CAGR of 9.90% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the global Next-Generation Biomanufacturing market— Illumina Inc., Thermo Fischer Scientific Inc., Oxford Nanopore Technologies plc, Agilent Technologies, Inc., BGI, PerkinElmer Inc., QIAGEN, Eurofins Scientific, F. Hoffmann-La Roche Ltd, Takara Bio Inc., and Others.

Next Generation Biomanufacturing Market Highlights

The global Next-Generation Biomanufacturing market is accounted to register a CAGR of 9.90% during the forecast period and is estimated to reach USD 54.0 billion by 2032.

The Next-Generation Biomanufacturing market is experiencing growth due to several factors. Advances in biotechnology, such as synthetic biology and genome editing, have revolutionized biomanufacturing processes, leading to increased efficiency, scalability, and product yields. Additionally, the growing demand for biopharmaceuticals, personalized medicine, and sustainable manufacturing practices further drives market expansion. Moreover, innovations in automation, analytics, and process control technologies optimize bioproduction workflows, contributing to the overall growth of the market.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Next Generation Biomanufacturing Market Research Report

Segment Analysis

The global Next-Generation Biomanufacturing market has been segmented into Type, Application, and End-User.

On the basis of Type, the market is segmented into Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing, and Downstream Biomanufacturing. The

Continuous Upstream Biomanufacturing segment captured the largest market share in the Next-Generation Biomanufacturing Market in 2023 due to its ability to enhance productivity, reduce costs, and improve process control. This approach enables continuous production of biologics, minimizing downtime and increasing overall efficiency. Moreover, advancements in bioreactor technology and process optimization further support the widespread adoption of continuous upstream biomanufacturing methods.

Based on application, the global Next-Generation Biomanufacturing market has been segmented into Monoclonal Antibodies, Hormones, Vaccines, Recombinant Proteins, and Others. The Monoclonal Antibodies application captured the largest market share in the Next-Generation Biomanufacturing Market in 2023 due to their widespread therapeutic applications in treating various diseases, including cancer, autoimmune disorders, and infectious diseases. The scalability and reproducibility of monoclonal antibody production processes make them suitable for large-scale biomanufacturing, driving their dominance in the market amidst growing demand for biopharmaceuticals.

Based on End-User, the global Next-Generation Biomanufacturing market has been segmented into Biopharmaceutical Companies, Research Institutions, and CMOs/CDMOs. The Biopharmaceutical Companies End-User captured the largest market share in the Next-Generation Biomanufacturing Market in 2023 due to their significant investments in innovative biomanufacturing technologies. These companies prioritize efficiency, scalability, and quality assurance in bioproduction processes to meet the growing demand for biopharmaceuticals. Additionally, their expertise in drug development and manufacturing, coupled with advancements in biotechnology, position them as key drivers of next-generation biomanufacturing adoption.

Regional Analysis

The global Next-Generation Biomanufacturing market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of the US and Canada. The Europe Next-Generation Biomanufacturing market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The Next-Generation Biomanufacturing market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Next-Generation Biomanufacturing market comprises the Middle East, Africa, and Latin America.

North America captured the largest market share in the Next-Generation Biomanufacturing Market due to factors such as a robust biotechnology industry, extensive research and development activities, and favorable regulatory environments. Additionally, the region benefits from significant investments in biomanufacturing infrastructure, advanced technologies, and a skilled workforce, positioning North America as a leader in the global biomanufacturing landscape.

Europe secured the second-largest market share in the Next-Generation Biomanufacturing Market owing to its strong presence of biopharmaceutical companies, advanced healthcare infrastructure, and supportive regulatory environment. Additionally, Europe's emphasis on innovation, collaborative research initiatives, and investments in biotechnology contribute to its prominence in next-generation biomanufacturing. Moreover, strategic partnerships between academia, industry, and government further support the region's growth in the market.

Asia-Pacific is experiencing the highest compound annual growth rate (CAGR) in the Next-Generation Biomanufacturing Market due to factors such as increasing investments in biotechnology, rising adoption of advanced manufacturing technologies, and growing demand for biopharmaceuticals. Moreover, supportive government initiatives, expanding healthcare infrastructure, and the presence of a skilled workforce contribute to the region's significant growth potential in biomanufacturing.

Furthermore, the rest of the world's Next-Generation Biomanufacturing market is divided into the Middle East, Africa, and Latin America. The rest of the world is experiencing growth in the Next-Generation Biomanufacturing market due to factors such as expanding biopharmaceutical industries, rising investments in research and development, and increasing adoption of advanced biomanufacturing technologies. Additionally, collaborations with global players and supportive regulatory frameworks further drive market expansion in these regions.

Key Findings of the Study

• The global Next-Generation Biomanufacturing market is expected to reach USD 54.0 billion by 2032, at a CAGR of 9.90% during the forecast period.


• The Asia-Pacific region is experiencing rapid growth in the Next-Generation Biomanufacturing market due to increasing investments in biotechnology, rising adoption of advanced manufacturing technologies, and growing demand for biopharmaceuticals.


• Based on application, the Monoclonal Antibodies segment was attributed to holding the largest market in 2023, with an approximate market share of 30–50%.


• Illumina Inc., Thermo Fischer Scientific Inc., Oxford Nanopore Technologies plc, Agilent Technologies, Inc., BGI, PerkinElmer Inc., QIAGEN, Eurofins Scientific, F. Hoffmann-La Roche Ltd, Takara Bio Inc. and Others are key players in the market.